Shares of DiaMedica Therapeutics, Inc. (NASDAQ:DMAC – Get Free Report) have earned a consensus rating of “Moderate Buy” from the five ratings firms that are covering the company, Marketbeat reports. One analyst has rated the stock with a sell rating and four have given a buy rating to the company. The average 12-month price objective among analysts that have covered the stock in the last year is $12.00.
Several equities analysts recently commented on DMAC shares. HC Wainwright reaffirmed a “buy” rating and issued a $12.00 price objective on shares of DiaMedica Therapeutics in a research report on Tuesday, August 11th. Weiss Ratings reissued a “sell (d-)” rating on shares of DiaMedica Therapeutics in a research report on Friday, July 17th.
Get Our Latest Stock Analysis on DiaMedica Therapeutics
DiaMedica Therapeutics Trading Down 2.0%
DiaMedica Therapeutics (NASDAQ:DMAC – Get Free Report) last released its quarterly earnings results on Monday, August 10th. The company reported ($0.19) EPS for the quarter, beating analysts’ consensus estimates of ($0.20) by $0.01. On average, equities analysts forecast that DiaMedica Therapeutics will post -0.84 earnings per share for the current year.
Institutional Investors Weigh In On DiaMedica Therapeutics
Several institutional investors and hedge funds have recently made changes to their positions in the stock. World Investment Advisors grew its holdings in shares of DiaMedica Therapeutics by 7.7% during the fourth quarter. World Investment Advisors now owns 36,975 shares of the company’s stock valued at $294,000 after buying an additional 2,650 shares during the last quarter. Bank of America Corp DE increased its position in shares of DiaMedica Therapeutics by 62.5% in the 1st quarter. Bank of America Corp DE now owns 42,768 shares of the company’s stock valued at $290,000 after acquiring an additional 16,446 shares during the period. AWM Investment Company Inc. acquired a new position in shares of DiaMedica Therapeutics in the 2nd quarter valued at $253,000. Renaissance Technologies LLC acquired a new position in shares of DiaMedica Therapeutics in the 1st quarter valued at $356,000. Finally, Sei Investments Co. raised its stake in DiaMedica Therapeutics by 100.0% in the 1st quarter. Sei Investments Co. now owns 111,320 shares of the company’s stock worth $754,000 after acquiring an additional 55,660 shares during the last quarter. 10.12% of the stock is currently owned by institutional investors and hedge funds.
About DiaMedica Therapeutics
DiaMedica Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing therapies for serious diseases affecting the kidneys and nervous system. The company’s research is centered on biological pathways that may support tissue protection and recovery in conditions with limited treatment options.
Its lead investigational product, DM199, is a recombinant form of human tissue kallikrein-1, an enzyme involved in the kallikrein-kinin system. DiaMedica has studied DM199 in acute ischemic stroke and kidney-related disorders, including severe acute kidney injury.
Featured Stories
- Five stocks we like better than DiaMedica Therapeutics
- Tesla Wants to Make Its Own Chips—What Could Go Wrong?
- IREN Limited’s AI Pivot Gains Traction—But Can Its Data Centers Deliver?
- PBF Energy’s Stunning Rally Faces a Critical Test
- Citi Stock Falls Despite Earnings Beat: What Investors Need to Know
Receive News & Ratings for DiaMedica Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DiaMedica Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
